Concepedia

Author

Sandra Navarra

University of Santo Tomas HospitalORCID

Also Known As

C. Tanasescu, Leonid D Zamora, S Navarra, S V Navarra, S. Navarra, S. V. Navarra, S.V. Navarra, Sandra V. Navarra, Sandra Navarra, Sandra V Navarra

183

Publications

8.5K

Citations

37

H-Index

54

Concepts

All Affiliations

University of Santo Tomas HospitalUniversity of Santo TomasMonash UniversityChiang Mai UniversityThe University of Melbourne
SN

About

Sandra Navarra is an author at University of Santo Tomas Hospital specializing in autoimmune disease, medicine, and lupus.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

3.2K

2

Public Health

7

7

304

3

Epidemiology

6

6

274

4

Allergy

1

1

67

5

Endocrinology

1

1

30

Sandra Navarra

×

51

Publications

7K

Citations

33

H-Index

YearCitations

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher,

The Lancet

2011

2K

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen,

Annals of the Rheumatic Diseases

2023

766

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

Kate Franklyn, Chak Sing Lau, Sandra Navarra,

Annals of the Rheumatic Diseases

2015

683

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Susan Manzi, Jorge Sánchez‐Guerrero, Joan T. Merrill,

Annals of the Rheumatic Diseases

2012

396

2021 DORIS definition of remission in SLE: final recommendations from an international task force

Ronald van Vollenhoven, George Βertsias, Andrea Doria,

Lupus Science & Medicine

2021

299

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Brad H. Rovin, Neil Solomons, William F. Pendergraft,

Kidney International

2018

290

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé,

Annals of the Rheumatic Diseases

2018

284

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial

Bernard R. Rubin, Robert Burton, Sandra Navarra,

Arthritis & Rheumatism

2004

183

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Michelle Petri, Ronald van Vollenhoven, Jill P. Buyon,

Arthritis & Rheumatism

2013

173

Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study

Vera Golder, Rangi Kandane‐Rathnayake, Molla Huq,

The Lancet Rheumatology

2019

146

Page 1